Drugs Made In America Acquisition (NASDAQ:DMAA) Stock Price Up 0.1% – Here’s Why

Shares of Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) shot up 0.1% during mid-day trading on Friday . The company traded as high as $10.44 and last traded at $10.44. 275 shares changed hands during mid-day trading, a decline of 99% from the average session volume of 38,713 shares. The stock had previously closed at $10.43.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Drugs Made In America Acquisition in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

Drugs Made In America Acquisition Stock Up 0.1%

The business’s 50 day moving average price is $10.38 and its two-hundred day moving average price is $10.32.

Drugs Made In America Acquisition (NASDAQ:DMAA) last announced its earnings results on Tuesday, November 18th. The company reported $0.07 EPS for the quarter.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Sandia Investment Management LP bought a new stake in Drugs Made In America Acquisition in the third quarter worth about $161,000. Quarry LP bought a new position in shares of Drugs Made In America Acquisition during the 3rd quarter valued at about $161,000. Shaolin Capital Management LLC acquired a new position in shares of Drugs Made In America Acquisition in the 2nd quarter worth approximately $1,020,000. JPMorgan Chase & Co. bought a new stake in shares of Drugs Made In America Acquisition in the 3rd quarter worth approximately $1,024,000. Finally, Clear Street LLC bought a new stake in shares of Drugs Made In America Acquisition in the 2nd quarter worth approximately $1,149,000.

About Drugs Made In America Acquisition

Drugs Made In America Acquisition Corp (NASDAQ: DMAA) is a special purpose acquisition company incorporated in Delaware with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company’s stated focus is on identifying and acquiring one or more operating businesses in the U.S. pharmaceutical sector, particularly those involved in the domestic manufacturing of approved drugs, active pharmaceutical ingredients or related contract development and manufacturing services.

Operating as a blank‐check vehicle, Drugs Made In America Acquisition holds its funds in a trust account pending the completion of an initial business combination.